Fig 1: Correlation between Inteleukin (IL)-13 and C-reactive protein (CRP) (A), eosinophil count (B), lymphocyte count (C), disease duration (D), IL-4 (E), IL-15 (F), and IL-17 (G), and a history of allergy, including 5-aminosalicylic acid (ASA) intolerance (H), concomitant corticosteroids (I).
Fig 2: Hsa_circ_0010957 regulates activation of STAT3 signaling via miR-125b. (A) Potential binding site and the mutant site of STAT3 3'UTR and miR-125b. (B) Luciferase assay showing overexpression of miR-125b decreased the luciferase activity of wide-type STAT3 3'UTR vector, while not the mutant vector. (C and D) STAT3 protein level after transfecting miR-125b mimics or inhibitor into CD4+ T cells of patients with SLE. (E) STAT3 and phosphorylated STAT3 protein level after transfecting hsa_circ_0010957 siRNA and miR-125b inhibitor into CD4+ T cells of patients with SLE. (F) Silence efficiency of STAT3 in CD4+ T cells of SLE detected by reverse transcription-quantitative PCR. (G-I) IL-18, IL-6 and IL-17 levels detected in cell supernatant after transfecting STAT3 siRNA into CD4+ T cells of patients with SLE. Data are shown as mean ± SD *P<0.05. NS, no significance; SLE, systemic lupus erythematosus; wt, wild-type; mut, mutant type; UTR, untranslated region; miR, microRNA; siRNA, small interfering RNA; NC, negative control; IL, interleukin.
Fig 3: Hsa_circ_0010957 depletion blocks IL-6 induced activation of STAT3 signaling. (A) STAT3 and phosphorylated STAT3 protein levels when CD4+ T cells were treated with IL-6 and transfected with hsa_circ_0010957 siRNA and miR-125b inhibitor. (B-D) IL-18, IL-6 and IL-17 levels detected in cell supernatant when CD4+ T cells were treated with IL-6 and transfected with hsa_circ_0010957 siRNA and miR-125b inhibitor. Data are shown as mean ± SD *P<0.05. NS, no significance; IL, interleukin; miR, microRNA; siRNA, small interfering RNA; NC, negative control.
Fig 4: Hsa_circ_0010957 modulates inflammatory cytokines secretion via miR-125b. (A) Overexpression or silencing efficiency of hsa_circ_0010957 or miR-125b in CD4+ T cells of SLE detected by reverse transcription-quantitative PCR. (B-D) IL-18, IL-6 and IL-17 levels detected in cell supernatant after CD4+ T cells were transfected with hsa_circ_0010957 siRNAs and miR-125b inhibitor. (E-J) Pearson's correlation analysis between hsa_circ_0010957 or miR-125b expressions in CD4+ T cells of SLE with inflammatory cytokines in serum of patients with SLE. Data are shown as mean ± SD *P<0.05. SLE, systemic lupus erythematosus; miR, microRNA; siRNA, small interfering RNA; NC, negative control; IL, interleukin.
Fig 5: Serum Interleukin (IL)-1ß (A), IL-4 (B), IL-5 (C), IL-12/23p40 (D), IL-13 (E), IL-13Ra2 (F), IL-15 (G), IL-17 (H), IL-33 (I), OSM (J), and eotaxin-1 (K) expression in relation to clinical remission in bio-naïve ulcerative colitis patients treated with Golimumab (GLM). * p < 0.05. The horizontal line inside the box represents the median. The length of the box represents the interquartile range between the first and the third quartiles. The error bars above and below the box represent 90th and 10th percentile values, respectively.
Supplier Page from Abcam for Human IL-17 ELISA Kit